Abstract:Background: Most randomized controlled trials with a time-to-event outcome are designed assuming proportional hazards (PH) of the treatment effect. The sample size calculation is based on a logrank test. However, non-proportional hazards are increasingly common. At analysis, the estimated hazards ratio with a confidence interval is usually presented. The estimate is often obtained from a Cox PH model with treatment as a covariate. If non-proportional hazards are present, the logrank and equivalent Cox tests may lose power. To safeguard power, we previously suggested a 'joint test' combining the Cox test with a test of non-proportional hazards. Unfortunately, a larger sample size is needed to preserve power under PH. Here, we describe a novel test that unites the Cox test with a permutation test based on restricted mean survival time. Methods: We propose a combined hypothesis test based on a permutation test of the difference in restricted mean survival time across time. The test involves the minimum of the Cox and permutation test P-values. We approximate its null distribution and correct it for correlation between the two P-values. Using extensive simulations, we assess the type 1 error and power of the combined test under several scenarios and compare with other tests. We investigate powering a trial using the combined test. Results: The type 1 error of the combined test is close to nominal. Power under proportional hazards is slightly lower than for the Cox test. Enhanced power is available when the treatment difference shows an 'early effect', an initial separation of survival curves which diminishes over time. The power is reduced under a 'late effect', when little or no difference in survival curves is seen for an initial period and then a late separation occurs. We propose a method of powering a trial using the combined test. The 'insurance premium' offered by the combined test to safeguard power under non-PH represents about a single-digit percentage increase in sample size. Conclusions: The combined test increases trial power under an early treatment effect and protects power under other scenarios. Use of restricted mean survival time facilitates testing and displaying a generalized treatment effect.

Adaptive Promising Zone Design for Cancer Immunotherapy with Heterogeneous Delayed Treatment Effect

Designing therapeutic cancer vaccine trials with delayed treatment effect

A Group Sequential Design and Sample Size Estimation for an Immunotherapy Trial with a Delayed Treatment Effect.

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Group Sequential Design with Maximin Efficiency Robust Test for Immunotherapy with Generalized Delayed Treatment Effect.

Design and Analysis of group-sequential clinical trials based on a modestly-weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance

M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect.

Design and Analysis of Clinical Trials in the Presence of Delayed Treatment Effect

Optimal Marker-Strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

A Bayesian Phase I/II Trial Design for Immunotherapy

SPIRIT: A Seamless Phase I/II Randomized Design for Immunotherapy Trials

BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity